ابو غازي
عضو نشط
- التسجيل
- 18 أكتوبر 2001
- المشاركات
- 129
William Sonoma Inc. Beat EPS Estimates By Leveraging Expenses And Inventories – Deutsche Banc Comments [WSM]
ANAHEIM, Calif. (Reuters) - CV Therapeutics Inc. (Nasdaq:CVTX - news) said on Wednesday that a pivotal trial of its experimental drug ranolazine met its main goal of allowing patients with cardiac pain to exercise for longer periods.
The news sent the biotechnology company's shares soaring almost 24 percent to $47.44 in afternoon trade on Nasdaq.
ANAHEIM, Calif. (Reuters) - CV Therapeutics Inc. (Nasdaq:CVTX - news) said on Wednesday that a pivotal trial of its experimental drug ranolazine met its main goal of allowing patients with cardiac pain to exercise for longer periods.
The news sent the biotechnology company's shares soaring almost 24 percent to $47.44 in afternoon trade on Nasdaq.